VivoSeq
Oncology

Peritoneal Carcinomatosis

3

Pipeline Programs↗

7

Active Trials↗

5

Companies Involved↗

Peritoneal Carcinomatosis is an early-stage landscape with 3 programs across 5 companies. The most active players are McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Gynecologic Oncology Group, Sichuan Clover Biopharmaceuticals, Inc..

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

70/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 2G

Gynecologic Oncology Group

1 program

Phase 2S

Sichuan Clover Biopharmaceuticals, Inc.

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalIpsen logo

Ipsen

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

29

clinical trials

Completed14 · 48%
Terminated6 · 21%
Active, not recruiting4 · 14%
Recruiting3 · 10%
Unknown status2 · 7%

Clinical Trials

Trial Activity

29 trials

PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis
Recruiting·UUniversity of California, Irvine·Phase 1·NCT06511037·10 enrolled
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel In Patients With Peritoneal Carcinomatosis
Recruiting·NNational University Hospital, Singapore·Phase 1·NCT05395910·36 enrolled
A Phase II Single Arm Study of Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal Carcinomatosis
Recruiting·MMohammad Haroon Asif Choudry·Phase 2·NCT07475286·22 enrolled
PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis
Active, not recruiting·UUniversity Hospital, Geneva·Phase 1·NCT04000906·18 enrolled
Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis
Active, not recruiting·UUniversity of California, Irvine·Phase 2·NCT04762953·40 enrolled
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin In Patients With Peritoneal Carcinomatosis
Active, not recruiting·NNational University Hospital, Singapore·Phase 1·NCT03172416·21 enrolled
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer: a Phase I Study
Active, not recruiting·UUniversity Hospital, Ghent·Phase 1·NCT05277766·45 enrolled
Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin
Completed·EErasmus Medical Center·Phase 1·NCT05379790·20 enrolled
Cytoreduction Followed by Normothermic Versus Hyperthermic Intraperitoneal Intraoperative Chemoperfusion (HIPEC): a Study in Peritoneal Carcinomatosis
Completed·UUniversity Hospital, Ghent·Phase 2·NCT01575730·45 enrolled
Assessing Safety of NIPOX in Peritoneal Carcinomatosis of CRC
Completed·IInstitut du Cancer de Montpellier - Val d'Aurelle·Phase 1·NCT03253133·19 enrolled
Treatment of Peritoneal Carcinomatosis With Pressurized IntraPeritoneal Aerosol Chemotherapy -
Completed·—·Phase 2·NCT03287375·143 enrolled
HIPEC for Peritoneal Carcinomatosis
Completed·—·Phase 2·NCT02040142·51 enrolled
Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis
Completed·Novartis logoNovartis·Phase 2·NCT00332696·64 enrolled
Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis
Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00491855·3 enrolled
Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis
Completed·Ipsen logoIpsen·Phase 3·NCT00216372·80 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)